| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9206135 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364247 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US10702536 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US10695354 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US10675287 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US9643929 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| US9763954 | SUNOVION PHARMS INC | Therapeutical uses of eslicarbazepine |
Sep, 2028
(4 years from now) | |
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(6 years from now) | |
| US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(8 years from now) | |
Aptiom is owned by Sunovion Pharms Inc.
Aptiom contains Eslicarbazepine Acetate.
Aptiom has a total of 11 drug patents out of which 0 drug patents have expired.
Aptiom was authorised for market use on 08 November, 2013.
Aptiom is available in tablet;oral dosage forms.
Aptiom can be used as treatment of partial-onset seizures, treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures, treatment of partial-onset seizures; treatment of partial-onset seizures in a patient with refractory partial-onset seizures, treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine, treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures.
The generics of Aptiom are possible to be released after 24 August, 2032.
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...
Dosage: TABLET;ORAL
APTIOM family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic